Teva Pharmaceutical Industries (TEVA) Amortization - Goodwill (2017 - 2024)

Teva Pharmaceutical Industries has disclosed Amortization - Goodwill across 6 years of filings, most recently posting $280.0 million for Q4 2024.

• Quarterly Amortization - Goodwill changed N/A year-over-year to $280.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $280.0 million (down 78.12% YoY) and the FY2024 annual result came in at $1.3 billion, up 82.86% from the prior year.
• Amortization - Goodwill retreated to $280.0 million in Q4 2024, from $600.0 million in the prior quarter.
• Over five years, Amortization - Goodwill peaked at $4.6 billion in Q3 2020 and troughed at $280.0 million in Q4 2024.
• A 4-year average of $1.1 billion and a median of $600.0 million in 2024 frame the typical range for Amortization - Goodwill.
• Annual changes were most pronounced in 2023 — Amortization - Goodwill retreated 6.04% — and 2024, when it slumped 42.86%.
• Tracing TEVA's Amortization - Goodwill over 4 years: stood at $4.6 billion in 2020, then sank by 89.2% to $500.0 million in 2022, then soared by 40.0% to $700.0 million in 2023, then plunged by 60.0% to $280.0 million in 2024.
• Business Quant data shows TEVA's Amortization - Goodwill at $280.0 million in Q4 2024, $600.0 million in Q3 2024, and $400.0 million in Q2 2024.